- Home
- IMRX
as 10-07-2025 3:30pm EST
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 232.9M | IPO Year: | 2021 |
| Target Price: | $17.75 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $10.08 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immuneering Corporation (IMRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Feinberg Peter | IMRX | Director | Oct 3 '25 | Buy | $6.67 | 7,500 | $50,025.00 | 156,766 | |
| Morales Mallory | IMRX | Chief Accounting Officer | Oct 1 '25 | Buy | $6.39 | 300 | $1,917.00 | 27,533 | |
| Neufeld Leah R | IMRX | CHIEF PEOPLE OFFICER | Oct 1 '25 | Buy | $6.38 | 800 | $5,103.36 | 23,344 | |
| Bookman Michael | IMRX | CHIEF LEGAL OFFICER, SECRETARY | Oct 1 '25 | Buy | $6.83 | 1,020 | $6,966.50 | 4,870 | |
| Feinberg Peter | IMRX | Director | Sep 30 '25 | Buy | $7.03 | 7,500 | $52,730.25 | 156,766 | |
| Feinberg Peter | IMRX | Director | Sep 29 '25 | Buy | $7.18 | 5,000 | $35,900.00 | 156,766 |
Latest Immuneering Corporation News
IMRX Breaking Stock News: Dive into IMRX Ticker-Specific Updates for Smart Investing
Argus Research
15 days ago
Daily – Vickers Top Insider Picks for 09/23/2025
Argus Research
3 months ago
Daily – Vickers Top Buyers & Sellers for 06/25/2025
Simply Wall St.
4 months ago
We're A Little Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
MT Newswires
4 months ago
Mizuho Raises Price Target on Immuneering to $10 From $8, Keeps Outperform Rating
GlobeNewswire
4 months ago
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
GlobeNewswire
4 months ago
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
GlobeNewswire
4 months ago
Immuneering to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
5 months ago
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
Compare IMRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMRX Immuneering Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.